Sector News

Don’t fall for Shire’s ‘lowball’ bid, Baxalta CEO urges. Be true to our solo prospects instead

August 12, 2015
Life sciences
Last week, Baxalta rejected a $30 billion buyout bid from Shire, pointing to its youth, its standalone prospects and a portfolio that just wouldn’t jibe with the Irish pharma’s. On Monday, its CEO hammered those points home once again for investors–and stressed that Shire’s proposal, as it stands, is “wholly inadequate.”
 
Baxalta’s leaders made the “correct decision” not to engage with the Dublin drugmaker, skipper Ludwig Hantson insisted, noting that the $45.23-per-share offer “wasn’t close” to where it should be if Shire wants Baxalta to come to the table.
 
“In some respects, the nature of Shire’s interest in Baxalta is puzzling. Is it trying to opportunistically acquire our attractive hemophilia, immunology and growing oncology platforms without true synergies? We have an attractive set of franchises and it would be a shame to hand it over for a lowball valuation,” Hantson said on a call with shareholders.
 
Sure, Shire could bring along tax advantages for the Illinois drugmaker, thanks to its Irish address. But that’s where the savings would end, Baxalta believes. Though the two companies both focus on rare diseases, there’s little overlap, with Baxalta’s focus mainly on plasma. Combining plasma with other biopharma businesses won’t make easy cost cuts, Hantson contends.
 
“An acquirer like Shire isn’t just going to find easy savings from a combination with dissimilar assets,” he said.
 
When it comes to Baxalta’s standalone prospects, though, Hantson’s outlook is much rosier. The company is aiming to launch 20 new products by 2020, which should help it generate more than $2.5 billion in risk-adjusted sales. Its infrastructure and manufacturing “will provide an excellent platform to grow value,” too, he said.
 
Some analysts, though, have applauded Shire’s decision to go after Baxalta–and quickly. Cowen & Co. analyst Ken Cacciatore, for one, views the proposal–initially brought to Baxalta just 9 days after it spun off from parent company Baxter–as “value-creating and appropriately aggressive,” he wrote in a Monday note to clients.
 
By Carly Helfand
 

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.